Latest News for: crispr

Edit

Pairwise Licenses Fulcrum� CRISPR Platform to Wild Bioscience

Nasdaq Globe Newswire 23 Feb 2026
Fulcrum� tools to support AI-driven crop trait development. Fulcrum� tools to support AI-driven crop trait development ... .
Edit

Pairwise Licenses Fulcrum® CRISPR Platform to Wild Bioscience

Caledonian Record 23 Feb 2026
Durham, North Carolina and Oxford, United Kingdom, Feb ... ....
Edit

New CRISPR Tool May Roll Back Antibiotic Resistance

The Daily Tribune - Bahrain 20 Feb 2026
Scientists at UC San Diego have created a new CRISPR-based, second generation Pro-Active Genetics (Pro-AG) system called pPro-MobV that can fight antibiotic-resistant bacteria, or ‘superbugs’ in a completely new way.
Edit

Statement of Changes in Beneficial Ownership (Form 4) (CRISPR Therapeutics AG)

Public Technologies 20 Feb 2026
) FORM 4 ... 0.5 ... CRISPR Therapeutics AG [CRSP] 5 ... C/O CRISPR THERAPEUTICS, 105 WEST FIRST STREET 3 ... C/O CRISPR THERAPEUTICS ... CRISPR Therapeutics AG published this content on February 20, 2026, and is solely responsible for the information contained herein.
Edit

Seek Labs Awarded $2 Million Federal Grant for a Novel CRISPR-Based, Mutation-Resistant Therapeutic to Combat ...

Business Wire 18 Feb 2026
SALT LAKE CITY--(BUSINESS WIRE)-- #AvianInfluenza--Seek Labs received a $2M USDA APHIS grant to develop a CRISPR-based, mutation-resistant avian influenza therapeutic in collaboration with CFIA ... .
Edit

Breakthrough CRISPR system could reverse antibiotic resistance crisis

Science Daily 18 Feb 2026
Now, scientists at UC San Diego have unveiled a powerful new CRISPR-based tool that doesn’t just ...
Edit

Watchmaker Genomics Licenses CRISPR-Cas9 Intellectual Property from Caribou Biosciences to Increase Throughput and Reduce Sequencing ...

The Galveston Daily News 17 Feb 2026
BOULDER, Colo.--(BUSINESS WIRE)--Feb 17, 2026-- ....
Edit

Watchmaker Genomics Licenses CRISPR-Cas9 Intellectual Property from Caribou Biosciences to Increase Throughput and Reduce Sequencing Cost per Sample

Pharmiweb 17 Feb 2026
“This license gives us the freedom to rethink normalization from first principles, using CRISPR-Cas9 in a way that’s orthogonal to editing but highly aligned with modern sequencing needs.” . Applying CRISPR-Cas9 Beyond Editing .
Edit

CRISPR breakthrough: Scientists from China remove HIV DNA from infected cells

India Today 16 Feb 2026
CRISPR breakthrough Scientists from China remove HIV DNA from infected cells ... .
Edit

Advancing CRISPR Precision: Liposome-Encapsulated Nucleic Acids and LNP Delivery Gain Momentum with Support from Creative Biolabs

GetNews 16 Feb 2026
Creative Biolabs provides end-to-end scientific support—from liposomal formulation design to next-generation LNP platforms tailored for CRISPR-Cas9, RNPs, and emerging editing tools ... LNP Delivery for CRISPR.
Edit

CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results

Nasdaq Globe Newswire 12 Feb 2026
ZUG, Switzerland and BOSTON, Feb. 12, 2026 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq. CRSP) today reported financial results for the fourth quarter and full year ended December 31, 2025 ... .
Edit

CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results (CRISPR Therapeutics AG)

Public Technologies 12 Feb 2026
12, 2026 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq ... CRISPR Therapeutics continues to advance its in vivo hematopoietic stem cell editing approach utilizing lipid nanoparticle (LNP)-mediated delivery through preclinical studies.
Edit

CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results (Form 8-K) (CRISPR Therapeutics AG)

Public Technologies 12 Feb 2026
CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results. ZUG, Switzerland and BOSTON, February 12, 2026 - CRISPR Therapeutics (Nasdaq ... About CRISPR Therapeutics.
Edit

Annual Report for Fiscal Year Ending December 31, 2025 (Form 10-K) (CRISPR Therapeutics AG)

Public Technologies 12 Feb 2026
We are a leading biopharmaceutical company focused on the development of CRISPR-based therapeutics, including by using CRISPR/Cas9 technology ... In 2023, CASGEVY became the first-ever approved CRISPR-based gene-editing therapy in the world.
Edit

AI, Genomics, and CRISPR Signal a New Phase of Biological Innovation

Nasdaq Globe Newswire 10 Feb 2026
As AI continues to move beyond software and automation, its impact on genomics and gene editing is becoming increasingly tangible ... .

Article Search

tools
×
×
×
×